These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28499961)

  • 61. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study.
    Bongaerts B; Arnold SV; Charbonnel BH; Chen H; Cooper A; Fenici P; Gomes M; Ji L; Khunti K; Kosiborod M; Medina J; Nicolucci A; Shestakova M; Shimomura I; Tang F; Watada H; Rathmann W
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941550
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ISPAD Clinical Practice Consensus Guidelines 2014. Sick day management in children and adolescents with diabetes.
    Brink S; Joel D; Laffel L; Lee WW; Olsen B; Phelan H; Hanas R;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():193-202. PubMed ID: 25182314
    [No Abstract]   [Full Text] [Related]  

  • 66. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
    Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
    Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude.
    Wallace TM; Matthews DR
    QJM; 2000 Jun; 93(6):369-74. PubMed ID: 10873187
    [No Abstract]   [Full Text] [Related]  

  • 71. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes in Adults and Glycemic Outcomes.
    Alkhiari R; Alzayer H; Aljazeeri J; Vanniyasingam T; Punthakee Z
    Can J Diabetes; 2018 Apr; 42(2):158-162. PubMed ID: 28662968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
    Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
    Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Insulin therapy for type 2 diabetes.
    Swinnen SG; Hoekstra JB; DeVries JH
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S253-9. PubMed ID: 19875560
    [No Abstract]   [Full Text] [Related]  

  • 77. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
    Marcinak J; Cao C; Lee D; Ye Z
    Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry.
    Nambam B; Silverstein J; Cheng P; Ruedy KJ; Beck RW; Paul Wadwa R; Klingensmith G; Willi SM; Wood JR; Bacha F; Thomas IH; Tamborlane WV;
    Pediatr Diabetes; 2017 May; 18(3):222-229. PubMed ID: 26970319
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.
    Khunti K; Ji L; Medina J; Surmont F; Kosiborod M
    Diabetes Obes Metab; 2019 Nov; 21(11):2349-2353. PubMed ID: 31215715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.